2BB score and signals
Monopar Therapeutics Inc.’s current 2BB score is 26 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 23 | Low |
| Momentum | 51 | Stable |
| Financial strength | 36 | Weak |
| Quality | 40 | Normal |
| Risk | 46 | Moderate |
Company facts
| Headquarters | Wilmette, Illinois, United States |
| Founded | 2014 |
| Employees | 22 |
| 52-week range | $50.07 – $124.42 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-03-25 | — | -1.1848 | — | $0.00 |
| 2026-11-11 | — | -0.8868 | — | $0.00 |
| 2026-08-10 | — | -0.6335 | — | $0.00 |
| 2026-05-14 | -0.46 | -0.8521 | $0.00 | $0.00 |
Related companies
